← Back to Clinical Trials
Recruiting NCT07446088

NCT07446088 Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07446088
Status Recruiting
Phase
Sponsor Ceragem Clinical Inc.
Condition Improving Blood Circulation
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-12-01
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-12-01 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is a single-center, open-label, exploratory clinical trial to evaluate the safety and efficacy of a statics electricity generator for improving blood circulation.

Eligibility Criteria

Inclusion Criteria: * Adults aged between 19 and 65 years * Individuals with a BMI of 30.0 kg/m² or less * Individuals without abnormal findings on hematology tests (CBC) Exclusion Criteria: * Patients with uncontrolled hypertension despite medication (defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg measured at rest) * Patients with medical conditions requiring the use of assistive devices (e.g., pacemaker, artificial joint, stent, prosthesis, etc.) * Patients with seizure disorders or a history of loss of consciousness (e.g., epilepsy, acute febrile convulsions such as those associated with severe fever, etc.), or those at high risk of electric shock due to such conditions * Patients with ventricular arrhythmias (e.g., ventricular tachycardia, history of coronary artery bypass surgery, etc.) and patients with neurological disorders (e.g., diabetic neuropathy, etc.)

Contact & Investigator

Central Contact

Myeongbae Shin, Researcher

✉ mbshin94@ceragem.com

📞 82-10-4373-2808

Principal Investigator

Kwang Yong Shim, MD

PRINCIPAL INVESTIGATOR

Wonju Severance Christian Hospital

Frequently Asked Questions

Who can join the NCT07446088 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, up to 65 Years, studying Improving Blood Circulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07446088 currently recruiting?

Yes, NCT07446088 is actively recruiting participants. Contact the research team at mbshin94@ceragem.com for enrollment information.

Where is the NCT07446088 trial being conducted?

This trial is being conducted at Wŏnju, South Korea.

Who is sponsoring the NCT07446088 clinical trial?

NCT07446088 is sponsored by Ceragem Clinical Inc.. The principal investigator is Kwang Yong Shim, MD at Wonju Severance Christian Hospital. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology